(wherein said rings may have one or more substituents selected from the group consisting of a hydroxyl group, a lower alkyl group, a lower acyl group, a lower alkoxy group and a halogen atom, and wherein the lower alkyl group, the lower acyl group and the lower alkoxy group may have one or more substituents).

4. (Amended-Clean Text) The compound or the salt thereof according to Claim 1, wherein A is a benzene ring (wherein said benzene ring may have one or more substituents selected from the group consisting of a hydroxyl group, a lower alkyl group, a lower acyl group, a lower alkoxy group and a halogen atom, and wherein the lower alkyl group, the lower acyl group and the lower alkoxy group may have one or more substituents).

5. (Amended-Clean Text) The compound or the salt thereof according to Claim 1, wherein L is $-NR^3-CO-$ and X is $-NR^5-CO-$ or $-NR^5-SO_2-$.

6. (Amended-Clean Text) The compound or the salt thereof according to, Claim 1, wherein L is $-CO-NR^3-$ and X is $-NR^5-CO$ or $-NR^5-SO_2-$.

9. (Amended-Clean Text) The compound or the salt thereof according to Claim 7, wherein R^{101} is a lower alkyl group (wherein the alkyl group may contain a ring structure, and may have one or more substituents).

P21587.A01

10. (Amended-Clean Text) The compound or the salt thereof according to Claim 7, wherein R^{103} is an alkyl group having one or more substituents containing one or more hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom.

12. (Amended-Clean Text) The compound or the salt thereof according to Claim 7, wherein the ring formed by R^{102} and R^{103} bound to each other together with the nitrogen atom to which they bind is a ring represented by the following general formula (XXII):



(XXII)

[in the formula, X represents $-CH_2-$, -O-, -S-, -NH- or NR^{108}- [in the formula, R^{108} represents a lower alkyl group, a lower acyl group, a phenyl group or a heterocyclic group (wherein the lower alkyl group, the lower acyl group, the phenyl group and the heterocyclic group may have one or more substituents)];

n represents an integer of 1 to 4;

R^{107} represents a hydroxyl group, an amino group, a cyano group, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a lower alkylcarbonyl group (wherein the

lower alkyl group, the lower alkoxy group, the lower alkylthio group and the lower alkylcarbonyl group may contain a ring structure, and may have one or more substituents), an aryl group (wherein the aryl group may have one or more substituents) or a heterocyclic group;

A3

m represents an integer of 0 to 4, and when two or more of R^{107} exist, respective R^{107}s are independent and may be the same or different].

14. (Amended-Clean Text) A medicament comprising as an active ingredient a substance selected from the group consisting of the compound according to Claim 1 and a physiologically acceptable salt thereof, and a hydrate thereof and a solvate thereof.

A4

18. (Amended-Clean Text) The compound according to Claim 1 or a physiologically acceptable salt thereof, which is a ligand for neuropeptide Y receptor.

A5

19. (Amended-Clean Text) Use of a substance selected from the group consisting of the compound according to Claim 1 and a physiologically acceptable salt thereof, and a hydrate thereof and a solvate thereof for manufacture of a medicament.

20. (Amended-Clean Text) A method for controlling ingestion, which comprises the step of administering an effective amount of a substance selected from the group consisting

of the compound according to Claim 1 and a physiologically acceptable salt thereof, and a hydrate thereof and a solvate thereof to a mammal including human.

A5

21. (Amended-Clean Text) A method for prophylactic and/or therapeutic treatment of a disease in which NPY is involved, which comprises the step of administering an effective amount of a substance selected from the group consisting of the compound according to Claim 1 and a physiologically acceptable salt thereof, and a hydrate thereof and a solvate thereof to a mammal including human.

A6

24. (Amended-Clean Text) A medicament for controlling ingestion, which comprises as an active ingredient a substance selected from the group consisting of the compound represented by the general formula (IV) according to Claim 22 and a physiologically acceptable salt thereof, and a hydrate thereof and a solvate thereof.

25. (Amended-Clean Text) A medicament for prophylactic and/or therapeutic treatment of diabetes, which comprises as an active ingredient a substance selected from the group consisting of the compound represented by the general formula (IV) according to Claim 22 and a physiologically acceptable salt thereof, and a hydrate thereof and a solvate thereof.

P21587.A01

26. (Amended-Clean Text) A medicament for prophylactic and/or therapeutic treatment of hypercholesterolemia, hyperlipidemia or arteriosclerosis, which comprises as an active ingredient a substance selected from the group consisting of the compound represented by the general formula (IV) according to Claim 22 and a physiologically acceptable salt thereof, and a hydrate thereof and a solvate thereof.

27. (Amended-Clean Text) Use of a substance selected from the group consisting of the compound represented by the general formula (IV) according to Claim 22 and a physiologically acceptable salt thereof, and a hydrate thereof and a solvate thereof for manufacture of a medicament.

28. (Amended-Clean Text) A method for controlling ingestion, which comprises the step of administering an effective amount of a substance selected from the group consisting of the compound represented by the general formula (IV) according to Claim 22 and a physiologically acceptable salt thereof, and a hydrate thereof and a solvate thereof to a mammal including human.

29. (Amended-Clean Text) A method for therapeutic and/or prophylactic treatment of a disease in which NPY is involved, which comprises the step of administering an effective amount of a substance selected from the group consisting of the compound